Protocols: Mylan’s EpiPen strategy stirs fresh outrage over price gouging; a flailing Woodford halts big bonuses
Forget Martin Shkreli. The bad-guy role in the pharma world has now been handed to Mylan, which has been hit with a tsunami of media …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
